Results from 3 of the trials have been formally published in peer‐reviewed journals: these have related to therapies for CNGA3‐associated achromatopsia [136, 142] (with 3‐year results published), CNGB3‐associated achromatopsia (6 month results published) [137] and GUCY2D‐associated LCA. Here, CNGB3 is linked to achromatopsia.